Gender-affirming hormone therapy (GAHT) is associated with significantly improved HIV outcomes for transgender, nonbinary, and other gender-diverse (trans) people in the U.S., according to a new study published in The Lancet HIV.
Gender-affirming hormone therapy (GAHT) is associated with significantly improved HIV outcomes for transgender, nonbinary, and other gender-diverse (trans) people in the U.S., according to a new study published in The Lancet HIV.
Leave A Comment